The US Food and Drug Administration (FDA) has granted clearance to INmune Bio’s investigational new drug (IND) application enabling initiation of a Phase I/II clinical trial of INKmune, a natural killer (NK) cell immunotherapy, to treat metastatic castration-resistant prostate cancer. 

The open-label, six-month trial will randomise patients to receive one of three doses of INKmune, as an outpatient treatment.

Immunologic and therapeutic efficacy are the two markers to be measured during the study period.

Immunologic efficacy will measure the memory-like NK cells increase in the blood while therapeutic efficacy will measure tumour response to INKmune therapy.

The trial will also study PMSA PET scan and circulating tumour DNA and novel biomarkers of tumour response.

A consultant to INmune Bio, Matt Rettig is the principal investigator of the trial.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Learn more about Strategic Intelligence

INmune Bio CEO RJ Tesi said: “Prostate cancer is one of the few solid tumours that has no immunotherapy options and chemotherapy, the standard-of-care, has suboptimal efficacy with measurable toxicities. 

“INKmune has the potential to provide a safe and effective therapeutic option for men with this difficult disease.”

The company plans to enrol the first of 30 patients in the second half of this year and expand the trial at four more clinical sites.

The goal of the expansion is to demonstrate short and long-term safety, the ability to control prostate cancer tumour burden and identify a dose of INKmune, which will be used in a further blinded randomised pivotal trial.

INKmune is delivered by a simple IV infusion to improve the function of the patient’s own NK cells. 

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell...

Read more

Thank you.

You will receive an email shortly. Please check your inbox to download the Whitepaper.

By Cytiva Thematic

You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our privacy policy.